MAIA Biotechnology: director Stan Smith received 38,871 shares

What happened Stan Smith, a director, received a grant of derivative securities totaling 38,871 shares on Sep 30, 2026. The filing lists the acquisition price as $0 and reports the transaction as a derivative award.

Key details

• Transaction date and price: Sep 30, 2026; acquisition type A (award/grant) at $0.00 per share.
• Shares owned after the transaction: not specified in the filing excerpt.
• Relevant footnotes:
  • F1: Options granted under the 2021 Equity Incentive Plan vest 100% on the grant date and are exercisable beginning that date.
  • F2: Securities are beneficially owned through The Stan V. Smith Trust Dated 1993.
• Filing date and reference: filed Oct 2, 2026 (Accession 0001878313-26-000099).

Why it may matter

• This filing reports a grant of stock options that vest fully and are immediately exercisable; it does not report a market sale or purchase of shares. A filing does not show why the insider traded or why the company acted.